APNHY:OTC-Aspen Pharmacare Holdings Limited (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | OTC

Last Closing Price

USD 6.82

Change

+0.12 (+1.79)%

Market Cap

USD 3.15B

Volume

300.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. The company offers various oral solid dose, liquids, semi-solids, steriles, biologicals, and active pharmaceutical ingredients. It also provides various therapeutic products, including general anaesthetics and muscle relaxants; and injectable anticoagulants comprising orgaran for the treatment of HIT and heparin based products under the Thrombosis brand. In addition, the company offers oncology, endocrinology, and women's health products, as well as nutritional infant milks. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.04 (+0.14%)

USD63.83B 37.72 17.60
MKGAF MERCK Kommanditgesellschaft au..

+4.50 (+3.15%)

USD61.98B 37.74 17.60
TKPHF Takeda Pharmaceutical Company ..

+1.22 (+3.34%)

USD57.55B 51.33 0.13
ESALY Eisai Co., Ltd

+1.75 (+1.94%)

USD25.68B 21.76 0.14
ESALF Eisai Co., Ltd

N/A

USD25.66B 21.85 0.14
SFOSF Shanghai Fosun Pharmaceutical ..

-0.02 (-0.36%)

USD17.25B 20.84 2.64
SGIOF Shionogi & Co., Ltd

-0.87 (-1.58%)

USD16.38B 15.12 0.08
SGIOY Shionogi & Co., Ltd

+0.29 (+2.12%)

USD16.32B 15.22 0.08
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

N/A

USD9.49B 904.00 16.09

ETFs Containing APNHY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.13% 54% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.13% 54% F 40% F
Trailing 12 Months  
Capital Gain 19.86% 78% C+ 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.86% 78% C+ 68% D+
Trailing 5 Years  
Capital Gain -70.21% 36% F 22% F
Dividend Return 2.53% 33% F 12% F
Total Return -67.68% 38% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -16.58% N/A N/A 13% F
Dividend Return 0.53% N/A N/A 31% F
Total Return -16.05% N/A N/A 13% F
Risk Return Profile  
Volatility (Standard Deviation) 31.77% N/A N/A 55% F
Risk Adjusted Return -50.52% N/A N/A 13% F
Market Capitalization 3.15B 91% A- 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.65 21% F 25% F
Price/Book Ratio 0.92 64% D 62% D-
Price / Cash Flow Ratio 0.38 18% F 40% F
EV/EBITDA 1.20 64% D 61% D-
Management Effectiveness  
Return on Equity 7.47% 83% B 67% D+
Return on Invested Capital -1.94% 59% F 35% F
Return on Assets 3.45% 85% B 78% C+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 57% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.